Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.69 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.67 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.67 |
| ▸ | STAT3 | P40763 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | MIF | P14174 | 2/20 | 0.58 |
| ▸ | BCL2 | P10415 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189483 | 1.00 | CRBN (0.69) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL20242290 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL22834201 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL20142514 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL20242552 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL22325167 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL21333201 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL22326316 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL30189563 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL30869200 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20260115297-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3725771-B1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-02-04 | — | — | EP | disclosed |
| EP-3841098-B1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| US-12465648-B2 | Heterobifunctional compounds as degraders of HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-10-23 | — | — | US | disclosed |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| EP-4598905-A2 | CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS | University of Florida Research Foundation, Incorporated (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3743069-B1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BIOVENTURES LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2020200291-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2020-10-08 | — | — | WO | disclosed |
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2020-10-01 | — | — | US | disclosed |
| WO-2020163823-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020156017-A1 | TARGETED UBIQUITINATION DEGRADATION BRD4 PROTEIN COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2020-08-06 | — | — | WO | disclosed |
| CN-111205282-A | ER protein modulators and uses thereof | 上海科技大学 | 2020-05-29 | — | — | CN | disclosed |
| WO-2020038415-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2020-02-27 | — | — | WO | disclosed |
| WO-2019170150-A1 | PROTEIN DEGRADATION TARGETING BCR-ABL COMPOUND AND ANTITUMOR APPLICATION THEREOF | 上海科技大学 | 2019-09-12 | — | — | WO | disclosed |
| WO-2019165189-A1 | PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190255041-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-08-22 | — | — | US | disclosed |
| WO-2019144117-A1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BIOVENTURES, LLC (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465648-B2 | Heterobifunctional compounds as degraders of HPK1 | HIPK1, MCL1, HYPK | CRBN 421/4885DDB1 473/4885HDAC1 1183/4885 |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | CRBN 330/4885DDB1 480/4885HDAC1 1716/4885 |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | CRBN 149/4885DDB1 1222/4885HDAC1 778/4885 |
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | ADRM1, VHL, MDM2 | CRBN 6/4885DDB1 518/4885HDAC1 2235/4885 |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | CRBN 109/4885DDB1 75/4885HDAC1 129/4885 |
| US-20260115297-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | TTK, ITK, CLK1 | CRBN 1072/4885DDB1 2640/4885HDAC1 969/4885 |
| US-20190255041-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | CRBN 120/4885DDB1 350/4885HDAC1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.